A Phase 1 Relative Bioavailability and Food Effect Study of ABBV-668 Extended-Release Formulations
Latest Information Update: 14 Oct 2024
At a glance
- Drugs ABBV 668 (Primary)
- Indications Immunological disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 08 Oct 2024 Status changed from active, no longer recruiting to completed.
- 29 Aug 2024 Status changed from recruiting to active, no longer recruiting.
- 17 Jul 2024 Planned End Date changed from 22 Sep 2024 to 19 Sep 2024.